Antioxidants may interfere with breast cancer treatment - CNN.com

NY Times request - urgent responses needed - Chemobarin

Email: janeengquist@juno.com

Raitt wanted credit for fixing 'sexy' isotope crisis: tape

Raitt wanted credit for fixing 'sexy' isotope crisis: tape: "sandipn, 09:09 AM EDT � Tuesday, June 9th, 2009

"What I think cannot be published. Cancer Survivor"

quick search - 'CA125' 25 results from May-June 2009 which should include ASCO + more

What do patients think about CA-125 monitoring in the follow-up? Results from a multicenter trial in 1,060 patients with ovarian cancer -- Oskay-Oezcelik et al. 27 (15): 5522 -- ASCO Meeting Abstracts

Prognostic impact of the time interval between primary surgery and start of first-line chemotherapy in patients with advanced ovarian cancer: Analysis of prospective randomized phase III trials -- Mahner et al. 27 (15): 5514 -- ASCO Meeting Abstracts

Predictive value of serum CA125 levels in women with persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC) treated with bevacizumab (Bev) on a Gynecologic Oncology Group (GOG) phase II trial -- Randall-Whitis et al. 27 (15): e16505 -- ASCO Meeting Abstracts

Predictive value of serum CA125 levels in women with persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC) treated with bevacizumab (Bev) on a Gynecologic Oncology Group (GOG) phase II trial -- Randall-Whitis et al. 27 (15): e16505 -- ASCO Meeting Abstracts

The relevance of rising CA-125 levels within the normal range in predicting recurrence in patients with advanced stage ovarian cancer: A validation study -- AbuShain et al. 27 (15): e16521 -- ASCO Meeting Abstracts

Does repeat usage of bevacizumab in patients with progressive recurrent ovarian cancer offer a survival advantage? -- Richardson et al. 27 (15): e16510 -- ASCO Meeting Abstracts

Clinical outcome of resection of liver metastasis in patients with ovarian cancer -- Neumann et al. 27 (15): e16545 -- ASCO Meeting Abstracts

Prognostic factors in ovarian cancer patients with brain metastases: Results of a German multicenter study -- El Khalfaoui et al. 27 (15): e16527 -- ASCO Meeting Abstracts

Quality of care in advanced ovarian cancer: How important is provider specialty? ASCO Meeting Abstract

the key point: Making trials matter: pragmatic and explanatory trials and the problem of applicability

"....Readers need to know ‘who, what, when and where’...."